Skip to main content
. Author manuscript; available in PMC: 2010 May 20.
Published in final edited form as: Clin Cancer Res. 2009 Feb 17;15(5):1730–1740. doi: 10.1158/1078-0432.CCR-08-2008

Fig. 1.

Fig. 1

Low doses of gemcitabine sensitize pancreatic cancer but not normal cells to E1B19K-deleted mutants. A, viruses used in the study with the respective deletions indicated. PT45 (B) and Suit2 (C) cells were infected with viruses and treated with 5 nmol/L (black) or 10 nmol/L (grey) gemcitabine. D, normal NHBE cells infected with mutants and treated with 5 nmol/L (black), 10 nmol/L (grey) or10 μmol/L (white) gemcitabine. Cells were analyzed for viability with the MTS assay 3 d after treatment; EC50 values were calculated and presented as percentages of virus-treated compared with control cells, as described in Materials and Methods. Data are the averages of three to four experiments ± SE; *P < 0.05 and **P < 0.01for B and C, and D is the average of one representative study in triplicate ± SE with *P < 0.05 compared with virus-treated cells.